JDRF Encouraged by Results of PROTECT Clinical Trial
October 20, 2023
October 20, 2023
NEW YORK, Oct. 20 (TNSres) -- JDRF, a non-profit dedicated to funding type 1 diabetes research, issued the following news release on Oct. 19, 2023:
The results of the PROTECT clinical trial shared today by Sanofi and presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) annual conference demonstrate that TZIELD, the first disease-modifying therapy available to delay clinical T1D in people at risk of developing the disease, can also be effective in newl . . .
The results of the PROTECT clinical trial shared today by Sanofi and presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) annual conference demonstrate that TZIELD, the first disease-modifying therapy available to delay clinical T1D in people at risk of developing the disease, can also be effective in newl . . .